- Home
- PLD vs REGN Comparison
PLD vs REGN Comparison
Compare PLD & REGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PLD
- REGN
- Stock Information
- Founded
- PLD 1983
- REGN 1988
- Country
- PLD United States
- REGN United States
- Employees
- PLD N/A
- REGN N/A
- Industry
- PLD Real Estate Investment Trusts
- REGN Biotechnology: Pharmaceutical Preparations
- Sector
- PLD Real Estate
- REGN Health Care
- Exchange
- PLD Nasdaq
- REGN Nasdaq
- Market Cap
- PLD 103.1B
- REGN 110.0B
- IPO Year
- PLD 1994
- REGN 1991
- Fundamental
- Price
- PLD $109.45
- REGN $681.58
- Analyst Decision
- PLD Buy
- REGN Buy
- Analyst Count
- PLD 17
- REGN 25
- Target Price
- PLD $129.41
- REGN $1,024.28
- AVG Volume (30 Days)
- PLD 4.9M
- REGN 857.0K
- Earning Date
- PLD 01-21-2025
- REGN 02-04-2025
- Dividend Yield
- PLD 3.51%
- REGN N/A
- EPS Growth
- PLD 2.06
- REGN 15.31
- EPS
- PLD 3.31
- REGN 40.43
- Revenue
- PLD $8,239,209,999.00
- REGN $13,847,100,000.00
- Revenue This Year
- PLD N/A
- REGN $10.24
- Revenue Next Year
- PLD $7.44
- REGN $4.30
- P/E Ratio
- PLD $33.07
- REGN $16.86
- Revenue Growth
- PLD 0.81
- REGN 5.72
- 52 Week Low
- PLD $100.82
- REGN $666.25
- 52 Week High
- PLD $135.76
- REGN $1,211.20
- Technical
- Relative Strength Index (RSI)
- PLD 53.33
- REGN 36.27
- Support Level
- PLD $103.23
- REGN $666.25
- Resistance Level
- PLD $112.00
- REGN $743.28
- Average True Range (ATR)
- PLD 2.48
- REGN 19.76
- MACD
- PLD 0.91
- REGN 0.45
- Stochastic Oscillator
- PLD 70.92
- REGN 19.90
About PLD Prologis Inc.
Prologis was formed by the June 2011 merger of AMB Property and Prologis Trust. The company develops, acquires, and operates around 1.2 billion square feet of high-quality industrial and logistics facilities across the globe. The company also has a strategic capital business segment that has around $60 billion of third-party AUM. The company is organized into four global divisions (Americas, Europe, Asia, and other Americas) and operates as a real estate investment trust.
About REGN Regeneron Pharmaceuticals Inc.
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases; Praluent for LDL cholesterol lowering; Dupixent in immunology; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and CRISPR-based gene editing (Intellia).